発表論文

Ikka T, Hatta T, Saito Y, Fujita M.

Does the act on the safety of regenerative medicine in Japan ensure "safety"?: Implications of low adverse event reporting. Stem Cell Reports. 2023.

橋本茜、市川佳世子、當山まゆみ、中山健夫、藤田みさお

第三者が関わる生殖補助医療：日本の実証研究から明らかになった課題 CBEL Report, 2023; 6(1).

Sawai T, Hatta T, Akatsuka K, Fujita M.

Human genome editing in clinical applications: Japanese lay and expert attitudes. Frontiers in Genetics. 2023; 14:1205092.

Gyngell C, Munsie M, Fujita M, Thiessen C, Savulescu J, Konstantinov EI.

Ethical analysis of the first porcine cardiac xenotransplantation. Journal of Medical Ethics. 2023

Akatsuka K, Hatta T, Sawai T, Fujita M.

Genome editing of human embryos for research purposes: Japanese lay and expert attitudes. Frontiers in Genetics. 2023; 14:1205067.

藤田みさお

自由診療による再生医療－5つの主張から考える倫理的課題 実験医学増刊. 2023;41(2): 36-40.

Ikka T, Fujita M, Hatta T, Isobe T, Konomi K, Onishi T, Sanada S, Sato Y, Tashiro S, Tobita M.

Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan. Stem Cell Reports. 2023; 18(3)613-617.

藤田みさお

ヒト人工配偶子作製に伴う倫理的課題 細胞．2023; 55(1): 20-22.

藤田みさお

日本で治療として提供される再生医療の現状と課題 B＆I．2023; 81(2): 152-156.

Urade M, Fujita M, Tsuchiya A, Mori K, Nakazawa E, Takimoto Y, Akabayashi A.

Facts and recommendations regarding when medical institutions report potential abuse to child guidance centers: A cross-sectional study. Pediatric Reports. 2022; 14(4): 479-490.

Murata M, Kawabe K, Hatta T, Maeda S, Fujita M.

Current status of umbilical cord blood storage and provision to private biobanks by institutions handling childbirth in Japan. BMC Medical Ethics. 2022; 23(1).

Fujita M, Hatta T, Ide K.

Current status of cell-based interventions in Japan. Cell Stem Cell. 2022; 29(9): 1294-1297.

Sato H, Fujita M, Tsuchiya A, Hatta T, Mori K, Nakazawa E, Takimoto Y, Akabayashi A.

Disclosing a diagnosis of autism spectrum disorder without intellectual disability to pediatric patients in Japan in early diagnostic stages and associated factors: A cross-sectional study. BioPsychoSocial Medicine. 2022; 16.

Barker RA, Boer GJ, Cattaneo E, Charo RA, Chuva de Sousa Lopes SM, Cong Y, Fujita M, Goldman S, Hermerén G, Hyun I, Lisgo S, Rosser AE, Anthony E, Lindvall O.

The need for a standard for informed consent for collection of human fetal material. Stem Cell Reports. 2022; 17(6): 1245-1247.

Hatta T, Ide K, Fujita M, Ikka T.

Financial risks posed by unproven stem cell interventions: Estimation of refunds from medical expense deductions in Japan. Stem Cell Reports, 2022.

Sawai T, Hatta T, Akatsuka K, Fujita M.

Public attitudes in Japan toward the creation and use of gametes derived from human-induced pluripotent stem cells. Future Science OA, 2021.

Akatsuka K, Hatta T, Sawai T, Fujita M.

Public attitudes in Japan toward the reproductive use of gametes derived from human-induced pluripotent stem cells. Future Science OA, 2021.

藤田みさお

治療との誤解－臨床試験に参加する患者の心理－ CBEL Reports, 2021; 4(1): 64-72.

Lovell-Badge R, Anthony E, Barker RA, Bubela T, Brivanlou AH, Carpenter M, Charo RA, Clark A, Clayton E, Cong Y, Daley GQ, Fu J, Fujita M, Greenfield A, Goldman SA, Hill L, Hyun I, Isasi R, Kahn J, Kato K, Kim J-S, Kimmelman J, Knoblich JA, Mathews D, Montserrat N, Mosher J, Munsie M, Nakauchi H, Naldini L, Naughton G, Niakan K, Ogbogu U, Pedersen R, Rivron N, Rooke H, Rossant J, Round J, Saitou M, Sipp D, Steffann J, Sugarman J, Surani A, Takahashi J, Tang F, Turner L, Zettler PJ, Zhai X．

ISSCR guidelines for stem cell research and clinical translation: The 2021 update. Stem Cell Reports. 2021.

Hyun I, Clayton EW, Cong Y, Fujita M, Goldman SA, Hill LR, Monserrat N, Nakauchi H, Pedersen RA, Rooke HM, Takahashi J, Knoblich JA.

ISSCR guidelines for the transfer of human pluripotent stem cells and their direct derivatives into animal hosts. Stem Cell Reports. 2021.

Ide K, Matsuoka N, Fujita M.

Ethical aspects of brain organoid research in news reports: An exploratory descriptive analysis. Medicina. 2021; 57(6):532.

Ide K, Koshiba H, Hawke P, Fujita M.

Guidelines are urgently needed for the use of preprints as a source of information. J Epidemiol. 2021; 31(1). 97-99.

藤田みさお、八田太一

「未検証の幹細胞治療」を提供することは倫理的に許容されるのか
―海外の医学系学会による評価と日本への示唆― 日本医事新報 2021; 5055: 50-53.

藤田みさお、一家綱邦、八田太一

国際幹細胞学会による未検証の幹細胞治療を行う際のインフォームド・コンセント基準
―再生医療法下で提供される治療に関する説明事項への示唆― 日本医事新報 2021; 5057: 52-55.

Crane AT, Shen FX, Brown JL, Cormack W, Ruiz-Estevez M, Voth JP, Sawai T, Hatta T, Fujita M, Low WC.

The American public is ready to accept human-animal chimera research Stem Cell Reports. 2020; 15(4): 904-810.

Sawai T, Minakawa T, Pugh J, Akatsuka K, Yamashita JK, Fujita M.

The moral status of human embryo‐like structures: Potentiality matters? EMBO Reports. 2020; 20(8): 32-36.

Sawai T, Sakaguchi H, Thomas E, Takahashi J, Fujita M.

The ethics of cerebral organoid research: Being conscious of consciousness. Stem Cell Reports. 2019; 13(1):470-477

Ozeki-Hayashi R, Fujita M, Tsuchiya A, Hatta T, Nakazawa E, Takimoto Y, Akabayashi A.

Beliefs held by breast surgeons that impact the treatment decision process for advanced breast cancer patients: A qualitative study. Breast Cancer: Targets and Therapy. 2019; 11: 221-229.

Sawai T, Hatta T, Fujita M.

Japan significantly relaxes its human-animal chimeric embryo research regulations. Cell Stem Cell. 2019; 24 (4): 513-51.

Fujita M, Tabuchi K.

A rebuttal to Akabayashi and colleagues' criticisms of the iPSC stock project. Journal of Medical Ethics. 2019; 45(7):476-477.

澤井努, 藤田みさお

オルガノイド研究の倫理的課題 特集オルガノイド再生医学 -ミニ臓器を作る挑戦と応用の可能性- 医学のあゆみ 2018; 264(8): 679-684.

藤田みさお

臨床倫理学―事実と価値判断の区別という観点から― 心身医学 2017; 57: 1040-1045.

Sawai T, Hatta T, Fujita M.

The Japanese generally accept human-animal chimeric embryo research but are concerned about human cells contributing to brain and gametes. Stem Cells Translational Medicine. 2017; 6(8): 1749-1750.

Sawai T, Hatta T, Fujita M.

Public attitudes in Japan towards human-animal chimeric embryo research using human induced pluripotent stem cells. Regenerative Medicine. 2017;12(3):233-248.

Takashima K, Takimoto Y, Nakazawa E, Hayashi Y, Tsuchiya A, Fujita M, Akabayashi A.

Discovery and informing study participants of incidental findings detected in brain magnetic resonance imaging studies: Review and multi-institutional study. Brain and Behavior. 2017;7(5):e00676.

Sawai T, Fujita M.

The problem of dual use in relation to decoded neurofeedback. AJOB Neuroscience. 2016; 7(4): 253-254.

Fujita M, Hatta T, Reina O, Akabayashi A.

The current status of clinics providing private practice cell therapy in Japan. Regenerative Medicine. 2016; 11(1): 23-32.

Takahashi S, Fujita M, Akabayashi A.

"Mottainai" embryos and the earthquake. J Clin Res Bioeth. 2015; 7: 258

Ikka T, Fujita M, Yashiro Y, Ikegaya H.

Recent court ruling in Japan exemplifies another layer of regulation for regenerative therapy. Cell Stem Cell. 2015; 17(5): 507-508.

一家綱邦，八代嘉美，藤田みさお，池谷博

再生医療を実施する自由診療クリニックに対する民事訴訟 日本医事新法　2015；4766: 14-16.

Fujita M, Hatta T, Sawai T, Takahashi J.

Risk of Tumorigenesis and Patient Hope. AJOB Neuroscience. 2015; 6: 69-70.

Fujita M, Hayashi Y, Tashiro S, Takashima K, Nakazawa E, Akabayashi A.

Handling incidental findings in neuroimaging research in Japan: Current state of research facilities and attitudes of investigators and the general population. Health Research Policy and Systems. 2014; 12: 58.

及川正範，藤田みさお，赤林朗

包括同意の諸要件とその倫理的背景―同意取得のあり方に関する一考察― 生命倫理　2014；25：235-243．

Fujita M, Yashiro Y, Suzuki M.

Throwing the baby out with the bathwater: A critique of Sparrow's inclusive definition of the term 'in vitro eugenics.' J Med Ethics. 2013 Aug 28.

田中美穂，児玉聡，藤田みさお，赤林朗

イングランドの小児緩和ケアに関する法政策・統計データ・資金体制・提供される医療の現状 日本公衆衛生雑誌 2013; 8: 462-470．

藤田みさお

生命・医療倫理の基礎 心身医学 2012: 52: 1117-1123．

藤田みさお，赤林朗

臨床における倫理問題への取り組み 日本内科学会2012; 101: 2059-2064.

Takahashi S, Fujita M, Fujimoto A, Fujiwara T, Yano T, Tsutsumi O, Taketani Y, Akabayashi A.

The decision-making process for the fate of frozen embryos by Japanese infertile women: A qualitative study. BMC Medical Ethics 2012; 13: 9.

藤田みさお，赤林朗

日本における幹細胞治療の現状と問題 日本医事新報 2011; 4562: 27-31.

藤田みさお

倫理的側面からみた糖尿病看護の実践と研究 倫理的側面から見た糖尿病看護の実践 日本糖尿病教育・看護学会誌 2011; 15: 81-83.

Fujita M, Matsui K, Monden M, Akabayashi A.

Attitudes of medical professionals and transplant facilities toward living donor liver transplantation in Japan. Transplantation Proceedings 2010; 42: 1453-9.

Fujita M, Slingsby BT, Akabayashi A.

Transplant tourism from Japan. American Journal of Bioethics 2010; 10(2): 24-6.

中田亜希子，藤田みさお，児玉聡，大屋博道，水野能文，赤林朗

医薬情報担当者（MR）の継続教育における倫理教育に関する現状調査 医薬品情報学　2010; 12: 61-68.

著作物

Akabayashi A, Fujita M.

The present and future of stem cell therapy in Japan. In: Uehiro T (ed). Ethics for the Future of Life, 9-19. Oxford Uehiro Center for Practical Ethics; 2013.

藤田みさお

「利益相反」 In：新版『医療倫理Q&A』編集委員会編．新版『医療倫理Q&A』太陽出版；2013

藤田みさお

脳画像を用いた研究における偶発的所見の取り扱いに対する研究者の見解と施設の実態 In：赤林朗編．『脳科学研究と倫理　資料集（2010年度）』．46-61．東京大学；2011